Primary duodenal follicular lymphoma successfully treated with rituximab

Aguiar-Bujanda, David; Quiñones-Morales, I.; Camacho-Galán, R.; Llorca-Martínez, I.; Rivero-Vera, José C.; Bohn-Sarmiento, Uriel; Aguiar-Morales, José

doi:10.1007/s12094-007-0088-2

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,11,13,15,16 Previous therapeutic modalities for PIFL have included surgical resection, radiotherapy, and chemotherapy with or without rituximab. 2,11,16 A "watchful waiting" policy has been employed in some asymptomatic patients according to their therapeutic intentions. Regarding the present patient, we treated him with R-CHOP because of leukemic disease at presentation and successfully induced complete remission.…”

Section: Discussionmentioning

confidence: 99%

“…1 Although conventional nodal FL and PIFL carry the same chromosomal abnormality of t(14;18), PIFL almost exclusively affects duodenum and small intestine and rarely infiltrates other organs or tissues. 2 Therefore, PIFL mostly stays in the I to II, but not III to IV, clinical stages. 2 We here report a characteristic case of leukemic FL with massive intestinal involvement at presentation.…”

Section: Introductionmentioning

confidence: 98%

“…2 Therefore, PIFL mostly stays in the I to II, but not III to IV, clinical stages. 2 We here report a characteristic case of leukemic FL with massive intestinal involvement at presentation.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Systemic Follicular Lymphoma with Massive Intestinal Involvement with Leukemic Manifestation

Ono

Aoki

Kato

et al. 2011

J Clin Exp Hematopathol

View full text Add to dashboard Cite

A 30-year-old man was referred to our hospital with leukocytosis and fecal occult blood. His white blood cell count was 30.2 × 10 9 /L with 79% small-to medium-sized lymphocytes. Surface antigen analysis revealed that these lymphocytes were positive for CD19, CD20, CD10, and CD23, but negative for CD5. The lymphocytes infiltrated the bone marrow. On endoscopic examination of the duodenum and jejunum, many small polypoid lesions were observed. A histologic picture of a biopsied lesion showed diffuse infiltration of small-to medium-sized lymphocytes in the submucosal region. On immunohistochemistry, these lymphocytes were positive for CD20, BCL2, and CD10 (weakly). Polymerase chain reaction analysis of cells from peripheral blood, bone marrow, and intestinal lesion showed a fusion product of BCL2 and immunoglobulin heavy chain (IGH) genes. The fused BCL2/IGH gene was also demonstrated by fluorescence in situ hybridization in the same cell sources. Computed tomography scanning showed marked wall thickening throughout the small intestine and enlarged mesenteric lymph nodes. A diagnosis of follicular lymphoma with massive intestinal involvement in a leukemic state was made. After 6 courses of rituximab-combined CHOP chemotherapy, complete remission was obtained. 〔J Clin Exp Hematopathol 51(2) : 135-140, 2011〕

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Systemic Follicular Lymphoma with Massive Intestinal Involvement with Leukemic Manifestation

Ono

Aoki

Kato

et al. 2011

J Clin Exp Hematopathol

View full text Add to dashboard Cite

show abstract

Gastrointestinal follicular lymphoma: review of the literature

et al. 2010

View full text Add to dashboard Cite

Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma. Although the duodenum and terminal ileum are considered to be the most common sites of origin, the development of wireless capsule endoscopy and double-balloon enteroscopy has increased the detection of GI-FL in every part of the small intestine. Approximately 70% of patients with GI-FL are estimated to have multiple lesions throughout the entire gastrointestinal tract. FL is a low-grade lymphoma that usually develops very slowly. If the lymphoma causes no symptoms, immediate treatment may not be necessary. Standard therapy has not yet been established for GI-FL, but chemotherapy, radiotherapy, monoclonal antibody therapy, or a combination of these therapies, is sometimes performed based on the therapeutic regimens for nodal FL. Regimens including conventional chemotherapy with rituximab, which achieve high response rates in nodal FL, are commonly used for GI-FL. The long-term clinical outcome of GI-FL is unclear. The results of a few series on the long-term outcomes of patients with GI-FL treated with conventional therapy indicate a median relapse-free time ranging from 31 to 45 months. On the other hand, in patients with GI-FL who were followed without treatment, the median time to disease progression was 37.5 months. Thus, whether to initiate aggressive therapy or whether to continue watchful waiting in patients with GI-FL is a critically important decision. Ongoing research on biomarkers to guide individualized GI-FL therapy may provide invaluable information that will lead to the establishment of a standard therapeutic regimen.

show abstract